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Abstract
C-Mpl is the receptor for thrombopoietin (TPO), the main megakaryocyte (MK) growth factor, and 
c-Mpl is believed to be expressed on cells of the hematopoietic lineage. As MKs have been shown 
to enhance bone formation, it may be expected that mice in which c-Mpl was globally knocked out 
(c-Mpl−/− mice) would have decreased bone mass because they have fewer MKs. Instead, c-Mpl−/
− mice have a higher bone mass than WT controls. Using c-Mpl−/− mice we investigated the basis 
for this discrepancy and discovered that c-Mpl is expressed on both osteoblasts (OBs) and 
osteoclasts (OCs), an unexpected finding that prompted us to examine further how c-Mpl regulates 
bone. Static and dynamic bone histomorphometry parameters suggest that c-Mpl deficiency results 
in a high bone turnover state with a net gain in bone volume. In vitro, a higher percentage of c-Mpl
−/− OBs were in active phases of the cell cycle, leading to an increased number of OBs. No 
difference in OB differentiation was observed in vitro as examined by real-time PCR and 
functional assays. In co-culture systems, which allow for the interaction between OBs and OC 
progenitors, c-Mpl−/− OBs enhanced osteoclastogenesis. Two of the major signaling pathways by 
which OBs regulate osteoclastogenesis, MCSF/OPG/RANKL and EphrinB2-EphB2/B4, were 
unaffected in c-Mpl−/− OBs. These data provide new findings for the role of MKs and c-Mpl 
expression in bone and may provide insight into the homeostatic regulation of bone mass as well 
as bone loss diseases such as osteoporosis.
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INTRODUCTION
Traditionally, skeletal and hematopoietic systems have been studied as separate entities. 
However, given their shared site of origin in the bone marrow cavity, it is broadly accepted 
that the two cell lineages would have the ability to exert local influence on each other. A 
growing body of evidence suggests that MKs and/or their growth factors play a role in 
skeletal homeostasis. Indeed, our group and others have shown that increased levels of MKs 
lead to amplified OB proliferation and phenotypes displaying increased bone mass (Kacena 
et al.,2004; Kacena et al.,2012; Kacena et al.,2005; Miao et al.,2004; Cheng et al.,2013; 
Meijome et al.,2015; Cheng et al.,2015; Ciovacco et al.,2010; Lemieux et al.,2010; Ciovacco 
et al.,2009).
Specifically, our laboratory has previously shown that mice deficient in GATA-1 or NF-E2, 
transcription factors that are necessary for normal MK differentiation, develop a striking 
increase in bone marrow MK number with a concomitant reduction in platelet number and a 
dramatic increase in trabecular bone (Kacena et al.,2004; Shivdasani et al.,1995; Shivdasani 
et al.,1997). Similarly, overexpression of thrombopoietin (TPO), the major MK growth 
factor, in mice results in an approximate 4-fold increase in bone marrow MK number and an 
osteosclerotic bone phenotype (Villeval et al.,1997; Yan et al.,1996). Because of the similar 
increase in bone marrow MK number and high bone mass phenotype, we previously 
postulated TPO acts upon MKs and these MKs subsequently activate OB lineage cells, 
leading to an increase in bone formation. Based in part on this model, Perry et al examined 
whether a reduction in MK number would result in a reduction in bone (Perry et al.,2007). 
To do this they also examined mice deficient in c-Mpl, the receptor for TPO, which is 
thought to be highly restricted to hematopoietic stem cells and cells of the MK lineage. 
Although c-Mpl−/− mice have a significant reduction in MK numbers (>80% reduction) (de 
Sauvage et al.,1996), Perry et al found no difference in bone phenotype between c-Mpl−/− 
mice and wild-type (WT) controls (Perry et al.,2007) when a decrease in bone formation 
may have been expected.
Based on these apparently contradictory findings we examined potential mechanisms 
leading to increased bone mass in c-Mpl−/− mice and investigated new parameters including 
the direct effect of c-Mpl deletion on cells of the bone cell and the enumeration of numbers 
of OB and OC numbers in c-Mpl−/− mice. We report important new findings that cells of the 
OC and OB lineage express c-Mpl, and that c-Mpl expression can impact both OC and OB 
growth and function and may shed light on the direct and indirect effects of c-Mpl in 
regulating skeletal homeostasis.
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METHODS
Mice
For these studies 5 month-old female and male c-Mpl−/− or knockout (on a C57BL/6 
background) and wild-type (WT) C57BL/6 mice were utilized. C-Mpl knockout mice were 
kindly provided by Genentech. Generation and breeding of c-Mpl knockout mice was 
previously described (Gurney et al., 1994; Tong and Lodish, 2004; de Sauvage et al.,1994). 
C57BL/6 mice were obtained from Jackson Laboratories. Three and thirteen days prior to 
sacrifice, mice were injected with 30mg/kg of calcein (IP) for dynamic histomorphometric 
determinations. All procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the Indiana University School of Medicine and followed NIH 
guidelines as well as the Guide for the Care and Use of Laboratory Animals.
Histology/Histomorphometry
The WT and cMpl−/− mice were administered an intraperitioneal injection of the 
fluorochrome calcein (30mg/kg) 13 and 3 days prior to sacrifice to label actively forming 
bone surfaces. Static and dynamic histomorphometric analysis of trabecular bone was 
performed on femurs as previously described (Feher et al.,2010; Warden et al.,2008). 
Histological measurements were made with a semiautomatic analysis system (Bioquant 
OSTEO 7.20.10, Bioquant Image Analysis Co.) attached to a microscope with an ultraviolet 
light source (Nikon Optiphot 2 microscope, Nikon). Measurements were done on one 
stained (static) and one unstained (dynamic) section for each animal.
µCT
Micro-computed tomography or µCT (Skyscan 1172) was used to quantify trabecular bone 
parameters of the distal femur as previously detailed (Feher et al.,2010; Warden et al.,2008; 
Weatherholt et al.,2013). µCT scanning was performed on the femur sequestered for 
histology. In brief, images were binarized, and three-dimensional bone volume parameters 
were calculated: trabecular bone volume fraction (BV/TV, %), trabecular number (Tb.N, 1/
mm), trabecular thickness (Tb.Th, mm), and trabecular separation (Tb.Sp, mm).
Biomechanics
Relative bone strength was determined by performing three-point bending of the left femur 
with a materials testing device (MTS Systems Corporation; Eden Prairie, MN) as previously 
detailed (Warden et al.,2008; Feher et al.,2010; Weatherholt et al.,2013). In brief, femurs 
were thawed to room temperature in a saline bath for two hours. Thereafter, each femur was 
tested in the anterior-posterior direction and stabilized with a static preload of 1 N before 
being loaded to failure with a crosshead speed of 10 mm/min. Force versus displacement 
data was gathered at 100 Hz, and the ultimate force (N), stiffness (N/mm), polar moment of 
inertia, ultimate stress (MPa), modulus (MPa), and toughness (MJ/m3) were derived.
Preparation of Neonatal Calvarial Cells (OB)
Neonatal murine calvarial OB cells were prepared as previously described (Horowitz et al.,
1994) from WT C57BL/6 and c-Mpl −/− mice. Our technique was a modification of the 
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basic method described by Wong (Wong and Cohn, 1975). Briefly, calvaria were dissected 
from neonatal mice and then treated with EDTA in PBS for 30 min. Calvaria were then 
subjected to sequential collagenase digestions (200U/mL). Fractions 3–5 (digestions 
incubated at 37°C for 20–35, 35–50, and 50–65 min, respectively) were collected and used 
as the OB starting population. These cells were ~90% OB or OB precursors based on 
previously reported established criteria (Horowitz et al.,1994; Simmons et al.,1982; Jilka and 
Cohn, 1981). OBs were seeded at 2x104 cells/ml (optimal pre-tested). OB in culture were 
maintained in αMEM supplemented with 10% fetal bovine serum and were further 
supplemented with ascorbic acid (50 µg/ml added on day 0 and at all feedings) and β-
glycerophosphate (5mM added starting on day 7 and all subsequent feedings). Cells were 
fed twice per week. Thrombopoietin (TPO) was added to some cultures. Multiple doses of 
TPO were tested (1–1000 ng/ml) and none of these doses resulted in an appreciable 
difference in OB proliferation (data not shown). Therefore, we selected the TPO dosage our 
group and others have utilized for stimulation of MKs (100 ng/ml).
In Vitro Osteoclast-like Cell Formation Models
OC-like cells were generated as previously described (Kacena et al.,2004). In brief, 2×106 
bone marrow (BM) cells/ml and 20,000 primary calvarial OB/ml were grown in α-MEM 
supplemented with 10% FCS and 10−8 M 1,25(OH)2D3 (Bruzzaniti et al.,2009). The media 
was changed every other day for 6–8 days (until OC were formed). Once OC formed, the 
cells were fixed with 2.5% glutaraldehyde in phosphate buffered saline for 30 minutes at 
room temperature and stained for TRAP. Only TRAP+ multinucleated cells (>3 nuclei) were 
quantified.
Immunoprecipitation Assays
For immunoprecipitation (IP) analyses, OB were rinsed with ice-cold PBS and lysed in 
modified RIPA (mRIPA) buffer (50 mM Tris-HCl, pH 7.4), 150 mM NaCl, 5 mM EDTA, 
1% NP40, 1% sodium deoxycholate, 0.1% SDS, 50 mM NaF, 1% aprotinin and 0.1mM 
Na3VO4). After a brief sonication, lysed cells were centrifuged at 13,000 rpm for 5 min at 
4°C to obtain soluble cell extracts. For immunoprecipitation (IP), approximately 150 µg of 
lysates were incubated with 3 µg of Anti-TpoR/c-Mpl antibody (Millipore) for 2 h at 4°C. 
After incubation, 20 µl of Protein G-agarose beads were added to individual tubes for 1 h at 
4°C. The beads were washed four times with mRIPA and once with 10 mM Tris-HCl, pH 
7.4. The IPs were eluted by boiling for 10 min with 40 µl of 2X Laemmli’s sample buffer 
with β-mercaptoethanol. Immunoblotting was carried out with anti-rabbit secondary 
antibody (Promega).
Cell Cycle Analysis
WT C57BL/6 and cmp-l −/− calvarial OBs were assessed on days 1, 3, 5, and 7 of culture. 
Cells were stained with equal volumes of staining buffer (0.1mg/ml propidium iodide 
+ 0.6% Nonidet P40 in PBS) and 2 mg/ml RNase as described previously (Srour et al.,
1992). The cells were mixed well and incubated on ice for 30 minutes. Data were collected 
on a FACS caliber flow cytometer (BDIS) and the percentage of cells in G0/G1 and S/G2+M 
phases were determined.
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Apoptosis Analysis
WT C57BL/6 and cmp-l −/− calvarial OBs were assessed for apoptosis on days 1, 3, 5, and 
7 of culture. Cells were washed once in DMEM followed by the addition of Annexin-V 
conjugated with Aallophycocyanin (APC). Cells were incubated on ice for 15 minutes. Cells 
were washed and resuspended in DMEM followed by the addition of 10µl of 10ng/ml 
propidium iodide. Cells were incubated at room temperature for another 10 minutes and data 
were collected on a FACS caliber flow cytometer.
Alkaline Phosphatase Activity
Alkaline phosphatase activity was determined by the colorimetric conversion of p-
nitrophenol phosphate to p-nitrophenol (Sigma) and normalized to total protein (BCA, 
Pierce) (Hughes and Aubin, 1998). Briefly, 2 day-old calvarial OB that had been cultured for 
14 days were washed 2x with PBS, subsequently lysed with 0.1% (vol/vol) Triton X-100 
supplemented with a cocktail of broad-range protease inhibitors (Pierce), subjected to two 
freeze-thaw cycles, and cleared via centrifugation. Lysates were incubated with 3 mg/ml p-
nitrophenol phosphate in an alkaline buffer, pH 8.0, (Sigma) for 30 min at 37°C. The 
reaction was stopped by the addition of 20 mM NaOH and read at 395 nM (GENios Plus, 
Tecan). The enzymatic activity of alkaline phosphatase was determined by comparison with 
known p-nitrophenol standards (Sigma).
Quantitative Analysis of Calcium Deposition
Calcium deposition was assessed by eluting Alizarin Red S from monolayers of neonatal 
calvarial OBs grown for 14 days in culture as previously described (Stanford et al.,1995). 
Briefly, monolayers were washed 2X with PBS, subsequently fixed in ice cold 70% (v/v) 
ethanol for 1 hr, then washed 2X with water. Monolayers were stained with 40mM Alizarin 
Red S (pH 4.2) for 10 min (room temperature, shaking), unbound dye was removed by 
washing with water (5X) and with PBS (1X for 15 minutes, room temperature, shaking). 
Bound Alizarin Red was eluted by incubating monolayers with 1% (v/v) cetylpyridinium 
chloride in 10mM sodium phosphate (pH 7.0) for 15 min (room temperature, shaking). 
Absorbance from aliquots was measured at 562 nm (GENios Plus, Tecan), and Alizarin Red 
concentrations were calculated from measured standards (Ca/mol of dye in solution).
Quantitative Real-Time PCR
Total RNA was isolated using Trizol Reagent as directed by the manufacturer (Invitrogen 
Corporation). 1ug of RNA isolated using Trizol Reagent was used to generate cDNA by 
reverse transcription according to the manufacturer’s instructions (First Strand cDNA 
Synthesis Kit for RT-PCR; Roche Applied Science). Quantitative Real-Time PCR (qRT-
PCR) reactions were performed in an ABI Prism 7900HT sequence detection system 
(Applied Biosystems) using Power SYBR Green PCR Master Mix reagent following the 
manufacturer’s instructions for relative quantification (Applied Biosystems).
For each gene analyzed, a calibration curve was performed and all the oligonucleotides were 
tested to ensure specificity and sensitivity. For each sample, arbitrary units were obtained 
using the standard curve and relative mRNA expression of GAPDH was used to normalize 
the amount of the investigated mRNA transcript. For each target gene, the corresponding 
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WT sample was used as the calibrator for relative expression. Primer pair sequences used 
were:
Alkaline phosphatase forward primer: 5’ GCTGATCATTCCCACGTTTT
Alkaline phosphatase reverse primer: 5’ CTGGGCCTGGTAGTTGTTGT
Osteocalcin forward primer: 5’ AAGCAGGAGGGCAATAAGGT
Osteocalcin reverse primer: 5’ TTTGTAGGCGGTCTTCAAGC
Type I collagen forward primer: 5’ CAGGGAAGCCTCTTTCTCCT
Type I collagen reverse primer: 5’ ACGTCCTGGTGAAGTTGGTC
GAPDH forward primer: 5’ CGTGGGGCTGCCCAGAACAT
GAPDH reverse primer: 5’ TCTCCAGGCGGCACGTCAGA
MCSF forward primer: 5’ CCCATATTGCGACACCGAA
MCSF reverse primer: 5’ AAGCAGTAACTGAGCAACGGG
OPG forward primer: 5’ CCGAGTGTGTGAGTGTGAGG
OPG reverse primer 5’ TGCAAACTGTGTTTTGCTCTG
RANKL forward primer: 5’ CATTTGCACACCTCACCATC
RANKL reverse primer: 5’ TCCGTTGCTTAACGTCATGT
EphB2 forward primer: 5’ GATGGTACATCCCCCATCAG
EphB2 reverse primer: 5’ ACGCACCGAGAACTTCATCT
EphB4 forward primer: 5’ CAACTGGATGAGAGCGAGAG
EphB4 reverse primer: 5’ GAGGCAGAGAACTGCAATGA
Statistics
Unless otherwise stated, all data are presented as the Mean ± 1 SD. All experiments were 
performed at least three times with duplicate or triplicate samples in each experiment. For in 
vivo studies, the sample size is presented in the corresponding figure legends. Student’s t-
test were performed when only two groups were compared. As male and female mouse 
bones exhibited virtually identical properties, for ease of reporting and to increase the 
sample size, data from male and female mice were combined for all of the in vivo data 
analysis. One-way factorial analyses of variances with LSD were used to make multiple 
group comparisons.
Two-way factorial analyses of variances were used to determine significant main effect 
contribution in cell co-culture groups, with BM genotype and OB genotype being the 
independent variables, as well as significant interaction effect between these independent 
variables. All analyses were performed with the Statistical Package for Social Sciences 
(IBM SPSS 19; SPSS Inc., Armonk, NY) software and were two tailed with a level of 
significance set at 0.05.
RESULTS
Trabecular Bone Phenotype of 20 Week-Old C-Mpl−/− Mice
Bones were assessed from male and female c-Mpl−/− and WT mice at 20 weeks. It should 
be noted that no significant differences were observed in body weights between C57BL/6 
Meijome et al. Page 6
J Cell Biochem. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and c-Mpl−/− mice (25.8±3.1g vs. 24.1±2.9g, respectively). µCT and static 
histomorphometry data (trabecular bone) are reported in Table 1. As detailed in Table 1 and 
illustrated in Figure 1, unexpectedly, bone volume/total volume (BV/TV) was elevated 2.2 
fold in c-Mpl−/− mice compared to WT controls as measured by static histomorphometry 
(p=0.005) and 3.4 fold in c-Mpl−/− mice compared to WT controls as measured by µCT 
(p<0.001). C-Mpl−/− femurs exhibited a significant increase in trabecular number (Tb.N, 3.8 
fold increase, p<0.001) with a concomitant decrease in trabecular spacing (Tb.Sp, 1.8 fold 
decrease, p<0.001) compared to WT controls as measured by µCT. No difference was 
detected in trabecular thickness (Tb.Th). Of interest, the structural model index or SMI, 
measured by µCT, was 2.00±0.005 for c-Mpl−/− femurs and 2.69±0.05 for WT control 
femurs and (p<0.001). As an SMI of 3 signifies a more rod-like bone architecture whereas 
an SMI of 0 signifies a more plate-like structure, c-Mpl deficiency resulted in a more plate-
like trabecular architecture.
As shown in Table 1 and Figure 1, examination of static bone histomorphometry parameters 
illustrated a significant increase in both the number of OBs/tissue area (N.Ob/TAR, 1.6 fold 
increase, p=0.05) and the number of OCs/tissue area (N.Oc/TAR, 2 fold increase, p=0.003) 
from the distal femur of the c-Mpl−/− mice when compared to the WT controls. This finding 
is not surprising given that OBs and OCs are typically coupled. Thus, it is not unusual to 
observe a significant increase in both OB and OC numbers. Dynamic bone 
histomorphometric analyses revealed no significant differences for the distal femur between 
c-Mpl−/− and WT with respect to bone formation rate/total volume (BFR/TV) or mineral 
apposition rate (MAR). These data, combined with the bone volume data from µCT and 
static histomorphometry, suggest c-Mpl−/− mice to have increased numbers of OBs that are 
similarly active/functional to that of WT mice. However, the increased number of OBs 
formed more total trabecular bone. As OC numbers were also elevated in c-Mpl−/− mice c-
Mpl deficiency produced a high bone mass phenotype, appearing by five months of age, as a 
result of a high turnover state; similar to what was observed in growing mice.
Anthropometrics, Cortical Bone, Biomechanical and Biomaterial Properties
Anthropometrics and cortical bone histomorphometry are reported in Table 2. 
Biomechanical and biomaterial property data are reported in Tables 2 and 3. With respect to 
femoral geometry, no significant differences were detected between c-Mpl−/− and WT mice 
for femoral length, mid-shaft width (medial to lateral), or mid-shaft height (ventral to 
dorsal). Consistent with the mid-shaft width and height, polar moment of inertia, calculated 
via µCT, also revealed no significant difference between c-Mpl−/−and WT femurs. Next, 
static and dynamic bone histomorphometric data was collected on cross-sectional femur 
specimens at the mid-shaft. As would be expected based on the gross femur width and 
height measurements, the cross-sectional area (CSA) was not different between WT and c-
Mpl−/− femurs (1.72±0.04 vs. 1.74±0.05, p=0.8) as assed by µCT. However, the bone area 
(BA) was significantly higher in WT femurs compared to c-Mpl−/− femurs (0.86±0.05 vs. 
0.72±0.02, p=0.005). As might be predicted based on the similar CSA, no difference in 
periosteal bone formation rate was detected. The increased BA observed in WT mice is 
likely due to the increased endocortical bone formation rate observed compared to c-Mpl−/− 
mice (p=0.03). With a similar outer geometry but a striking increase in bone area, it would 
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be predicted that the WT bones would be stronger and stiffer than c-Mpl−/− bones. 
Specifically, the WT femurs were 18.6% stronger than c-Mpl femurs (p<0.001) as 
determined by examining the peak load. Similarly, the WT femurs were 15.0% stiffer than c-
Mpl femurs (p=0.02).
C-Mpl is expressed on both Osteoblast and Osteoclast Lineage Cells
Since global deficiency of c-Mpl resulted in a high bone mass phenotype by 5 months of age 
with changes in both OB and OC parameters observed in vivo, we investigated possible 
mechanisms leading to this phenotype. First, we determined whether cells of the OB lineage 
express c-Mpl. As shown in Figure 2A, immunoprecipitation studies demonstrated the 
expression of c-Mpl in MKs (positive control) and in WT OBs, but not in c-Mpl−/− OBs 
(negative control). With respect to expression in OC lineage cells, we recently reported that 
primary bone marrow macrophages (OC progenitors) as well as two OC-like cell lines 
(RAW264.7 and a PAX5 Spleen Cell Line generated by M. Horowitz) all expressed c-Mpl 
albeit at lower levels than that observed in MKs (Bethel et al.,2015).
C-Mpl Negatively Regulates Osteoblast Proliferation
To begin to understand the role of c-Mpl expression in OB function, we next sought to 
determine whether c-Mpl expression affected OB number or cell cycle regulation. To 
accomplish this, equal numbers of WT and c-Mpl−/− OBs were cultured and assessed every 
other day (days 1, 3, 5 and 7) for the total number of viable OBs (trypan blue exclusion) 
produced in culture as well as cell cycle status. As demonstrated in Figure 2, c-Mpl−/− OB 
cultures produced significantly more cells than their WT counterparts (Figure 2B) and c-Mpl
−/− OBs entered active phases of cell cycle at a higher rate than WT OBs (Figure 2C). Of 
interest, we also cultured OBs in the presence or absence of TPO (kindly provided by 
Genentech). Supplementation with 100 ng/ml of TPO did not have an effect on total number 
of OB progeny or their cell cycle. Finally, we also assessed apoptosis by examining the 
expression of Annexin V. In all cases, less than 2% of the OBs were Annexin V positive, 
suggesting that apoptosis did not alter proliferation or cell cycle status of OBs in culture.
C-Mpl Expression Does Not Affect Osteoblast Differentiation In Vitro
To understand the effects of c-Mpl expression and signaling on OB differentiation, we 
examined the following 4 groups of cells: WT OB, WT OB + TPO, c-Mpl−/− OB, and c-
Mpl−/− OB + TPO. Cells were cultured under osteogenic conditions as detailed above. As 
shown in Figures 2D and 2E, we assessed alkaline phosphatase activity and measured bound 
calcium as a functional measure of mineralization after 14 days. No significant differences 
were detected between WT and c-Mpl−/− OBs. Furthermore, the addition of 100 ng/ml of 
TPO did not have a notable effect on WT or c-Mpl−/− OBs.
To further examine the effects of c-Mpl expression in OB differentiation we cultured WT 
and c-Mpl−/− OBs under osteogenic conditions as above and on day 14 examined mRNA 
expression of the following genes: alkaline phosphatase, type I collagen, and osteocalcin. As 
illustrated in Figure 2F, no significant differences in mRNA expression of these genes were 
observed between WT and c-Mpl−/− OBs.
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The Effects of c-Mpl Expression on Osteoclasts
We recently demonstrated that TPO significantly enhanced osteoclastogenesis when bone 
marrow marcophages (BMMs) were used as a source of OC progenitors, and that fewer OCs 
were generated from c-Mpl−/− BMMs as compared to those generated from WT BMMs 
(Taylor et al.,2008). As fewer OCs were generated from c-Mpl−/− BMMs in vitro but higher 
numbers of OCs were observed in c-Mpl−/− mice in vivo, and because we found that OBs 
also express c-Mpl, we sought to determine whether c-Mpl−/− OBs promote 
osteoclastogenesis. To accomplish this, we performed mix-and-match experiments in which 
OCs were generated by co-culturing of OB and BM supplemented with PGE2 and Vitamin 
D3. Specifically, WT or c-Mpl−/− OBs were co-cultured with BM generated from WT or c-
Mpl−/− mice. TRAP+ multinucleated (≥3 nuclei) cells from the 4 experimental groups were 
analyzed for three parameters: OC number, average nuclei/OC, and average OC surface area. 
As shown in Figure 3, significant main effect differences were found for both OB and BM 
genotype with respect to OC number (Figure 3A), number of nuclei/OC (Figure 3B), and 
OC surface area (Figure 3C). Specifically, c-Mpl−/− OBs supported osteoclastogenesis 
better than WT OBs, while WT BM cells supported osteoclastogenesis more effectively than 
c-Mpl−/− BM cells. Notably, a significant interaction was observed between c-Mpl−/− OB 
genotype and WT BM genotype with increased OC surface area (Figure 3) and increased 
OC nuclei number (Figure 3B), but not for total OC number (Figure 3A). Finally, as detailed 
above, our previous independent studies culturing BMMs in the presence of M-CSF and 
RANKL confirmed co-culture statistical analyses showing that WT BM cells better support 
osteoclastogenesis than c-Mpl−/− BM cells (Taylor et al.,2008).
C-Mpl Expression Does Not Affect M-CSF, OPG, RANKL, Eph B2, or Eph B4 expression in 
Osteoblasts
To further understand the mechanism by which expression of c-Mpl on OBs regulates 
osteoclastogenesis we cultured WT OBs and c-Mpl−/− OBs under osteogenic conditions and 
examined mRNA expression of the following genes: RANKL, OPG, and M-CSF. As shown 
in Figure 4, no significant differences were detected suggesting that c-Mpl expression on 
OBs does not affect OB expression of these known regulators of osteoclastogenesis. The 
EphrinB2-EphB2/B4 signaling pathway has also been implicated in OB-mediated 
osteoclastogenesis. Thus, we also determined whether c-Mpl expression altered OB-specific 
expression of EphB2 or EphB4. No significant differences were detected (Figure 4). 
Although c-Mpl−/− OBs were able to better support osteoclastogenesis than their WT 
counterpart, the exact mechanism for this enhanced support remains to be determined.
DISCUSSION
C-Mpl is a member of the type I cytokine receptor family. The receptor along with its ligand, 
TPO, were first proposed to play a role in megakaryopoiesis when experiments showed that 
antisense oligonucleotides to c-Mpl reduced MK colony formation (Methia et al.,1993). 
Upon binding to c-Mpl, TPO has been shown to promote the proliferation and differentiation 
of MK progenitor cells (Broudy et al.,1995; Kaushansky et al.,1994). The roles of TPO and 
c-Mpl were further clarified when a mouse model deficient in the gene for TPO exhibited a 
greater than 80% decrease in MK and platelet numbers (de Sauvage et al.,1996). In their 
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original study of c-Mpl−/− mice, Gurney et al. noted a marked decrease in MK number, but 
found no change in the number of mature red blood cells, white blood cells, neutrophils, or 
eosinophils. The role of TPO and c-Mpl in other hematopoietic lineages was later 
elucidated. Solar et al found that c-Mpl is expressed in early hematopoietic cells and that 
TPO is able to activate quiescent progenitors (Solar et al.,1998). This is consistent with the 
observation that c-Mpl−/− and TPO−/− mice display diminished levels of erythroid, 
myeloid, and multipotential progenitor cells (Carver-Moore et al.,1996). Indeed, subsequent 
studies by Carver-Moore et al. showed a significant decrease in all hematopoietic 
progenitors, including myeloid lineage cells. As OCs are known descendents of myeloid 
progenitors, it would be understandable if OCs were altered in the c-Mpl deficient mice. 
Furthermore, our laboratory recently showed that OC progenitors express c-Mpl, that 
stimulation of OC progenitors with TPO enhances OC formation in vitro, and that binding of 
TPO to c-Mpl is required for TPO to enhance OC formation in vitro (Taylor et al.,2008). 
Thus, like MK lineage cells, OC numbers may be expected to be decreased in c-Mpl−/− 
mice, in part because with the loss of c-Mpl, the ability of TPO to enhance 
osteoclastogenesis would be largely suppressed and because of the defect observed in 
myeloid lineage cells. Interestingly, as detailed in Table 1, OC number was significantly 
higher in c-Mpl−/− mice compared to WT controls. These in vivo findings along with in 
vitro studies are discussed in further detail below.
As mentioned above, we have demonstrated that increased levels of bone marrow MKs can 
promote bone formation (Kacena et al.,2005; Kacena et al.,2004). In light of c-Mpl’s role in 
megakaryopoiesis and osteoclastogenesis, we aimed to further understand the c-Mpl−/− 
bone phenotype. Perry et al previously examined the bone phenotype of 12 week-old c-Mpl 
deficient mice (Perry et al.,2007). However, we have previously found that the high bone 
mass phenotype observed in mice with upregulated numbers of MKs (e.g. GATA-1 and NF-
E2 deficient mice) was not present until approximately 4 months of age (personal 
observation MAK and (Kacena et al.,2004; Kacena et al.,2005)). Therefore, here we have 
examined the bone phenotype of 20 week-old c-Mpl−/− and WT control mice.
Although Perry et al observed no difference in bone phenotype in 12 week-old mice, they 
predicted a decrease would be observed based on a reduction in the number of MKs (Perry 
et al.,2007). We report 20-week-old c-Mpl−/− mice to have a high bone mass phenotype 
(~2–3 fold increase) compared to WT controls. Examining biomechanical properties, femurs 
from WT mice are stronger and stiffer than those of c-Mpl−/− mice. Of importance, using 
static and dynamic bone histomorphometry we demonstrated that c-Mpl−/− mice had 
increased numbers of OBs (N.Ob/TAR), although OB activity appeared unchanged (BFR 
and MAR). In addition, OC number (N.Oc/TAR) was significantly elevated with c-Mpl 
deficiency. These findings, in combination with the increased number of OBs and high bone 
mass phenotype, suggest that c-Mpl deficiency results in a high bone turnover state with a 
net gain in bone volume.
How this could occur in light of previous postulations that MKs stimulate OB number and 
bone formation requires some historical background as well as new data. While establishing 
the role of c-Mpl in MKs and primitive hematopoietic cells, early papers speculated that the 
receptor is mainly restricted to hematopoietic lineages (Alexander et al.,1996; Mignotte et 
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al.,1994; de Sauvage et al.,1998). To our knowledge, c-Mpl has never been identified in 
mesenchymal lineage cells. We present the new observation that c-Mpl is expressed in cells 
of the OB lineage (Figure 2) in addition to our previous finding that c-Mpl is expressed in 
OC progenitors (Bethel et al.,2015). With respect to OB lineage cells, c-Mpl−/− OB cultures 
contained significantly more OBs over a 7 day time period and a larger percentage of 
cultured c-Mpl−/− OBs were in active phases of the cell cycle between days 3 and 7 
compared to WT OBs (Figure 2). Despite significant effects on OB proliferation, our data 
show no significant difference in differentiation between c-Mpl−/− and WT OBs, as 
assessed by functional alkaline phosphatase and mineralization assays, and mRNA 
expression of alkaline phosphatase, type I collagen, and osteocalcin as markers of OB 
differentiation. Thus, our in vitro data demonstrate that the loss of c-Mpl expression 
increases OB proliferation, yet does not appear to affect OB differentiation, which is 
consistent with an increase in OB number but no change in BFR in vivo.
With respect to in vitro osteoclastogenesis we found OC progenitors express c-Mpl (Bethel 
et al.,2015), WT BM cells respond to OB mediated regulation of osteoclastogenesis to a 
higher degree than c-Mpl−/− BM cells (Figure 3), and c-Mpl−/− OBs supported 
osteoclastogenesis better than WT OBs (Figure 3). Next, in an attempt to further understand 
how c-Mpl deficient OBs better support osteoclastogenesis, we examined OB expression of 
known regulators of osteoclastogenesis (Figure 4). As no differences were detected in the 
RANKL/OPG/MCSF or EphrinB2-EphB2/B4 axes, these data suggest that c-Mpl−/− OBs 
promote osteoclastogenesis through yet an unidentified pathway(s).
In summation, global deficiency of c-Mpl results in a high bone mass phenotype that 
develops with age. Complex interactions between MKs, OBs, OCs, TPO signaling, and c-
Mpl expression in OB and OC progenitors regulate skeletal homeostasis. Figure 5 presents a 
model summarizing our current understanding of these complex regulations based on our 
present findings and previously published data. The multiple and varied direct and indirect 
effects of TPO, c-Mpl, and MKs must be teased out to fully understand their impact on 
skeletal homeostasis. Use of tissue specific knockout and tissue specific overexpressing mice 
will be important in clarifying these issues and determining whether therapies targeting MKs 
and/or TPO/c-Mpl may prove beneficial for treatment of bone loss disorders such as 
osteoporosis.
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Figure 1. 
Representative images of distal femurs from 20 week-old WT and c-Mpl−/− mice. A) µCT 
reconstructions show the high bone mass phenotype in c-Mpl−/− mice compared to WT 
controls. B) Histological sections stained with Von Kossa show the significant increase in 
mineralized bone matrix in c-Mpl−/− femurs compared to that observed in WT femurs 
(original magnification 5X). C) TRAP staining illustrates the significant increase in OCs in 
c-Mpl−/− mice compared to WT controls (original magnification 20X).
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Figure 2. 
A) Neonatal calvarial OB lineage cells express c-Mpl as shown by immunoprecipitation of 
protein lysates from 2 day WT and c-Mpl−/− calvarial OBs and MKs, probed with 
antibodies raised against c-Mpl, shows that WT OBs express c-Mpl. B–F) Proliferation and 
differentiation of WT and c-Mpl−/− OBs. B&C) WT and c-Mpl−/− OBs were cultured and 
OB number (B) and cell cycle status (C) was assessed every other day by counting the 
number of cells excluding trypan blue and by staining OBs with propidium iodide, 
respectively. Annexin V expression was also determined. In all cases, less than 2% of the 
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OBs were Annexin V positive, suggesting that apoptosis was not detected. Data shown in 
Figure B reveal that the c-Mpl−/− OB cultures have more cells than do their WT 
counterparts. Data in Figure C illustrates that the c-Mpl−/− OBs enter active phases of cell 
cycle at a higher rate than WT OBs. These data suggest that the loss of c-Mpl most likely 
alters the rate at which c-Mpl−/− OBs enter S-G2M and therefore increases the total number 
of cells. D–F) To analyze the role of c-Mpl in OB differentiation, two day calvarial OBs 
were generated from WT and c-Mpl−/− mice. OBs were cultured under osteogenic 
conditions (ascorbic acid and and β-glycerophosphate supplementation) for 14 days in the 
presence or absence of TPO (100ng/ml) and alkaline phosphatase activity (D) and bound 
calcium as a marker of mineralization was measured (E). F) Real-time PCR was used to 
determine mRNA expression of alkaline phosphatase, type I collagen, and osteocalcin. No 
significant differences were detected suggesting that c-Mpl expression does not affect OB 
differentiation or expression of the genes examined.
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Figure 3. 
Histomorphometric analysis of OCs generated by co-culture of WT and c-Mpl−/− OBs with 
WT and c-Mpl−/− bone marrow (BM) supplemented with PGE2 and Vitamin D3 (A–C). 
Representative micrographs (original magnification 40X) from each of the 4 experimental 
groups are shown (D). Once OCs were visible (~7 days for co-cultures), cells were fixed and 
stained for tartrate resistant acid phosphatase (TRAP), and the TRAP+ multinucleated (≥3 
nuclei) cells from the 4 experimental groups were analyzed as follows: 1) OC number (A); 
2) Average nuclei/OC (B); and 3) Average OC surface area (C). Significant main effect 
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differences were found for both OB genotype and BM genotype for OC number, number of 
nuclei/OC, and OC surface area. Specifically c-Mpl−/− OBs better support 
osteoclastogenesis than do WT OBs, while WT BM better supports osteoclastogenesis than 
does c-Mpl−/− BM. Importantly, a significant interaction was observed between OB 
genotype and BM genotype for OC surface area and nuclei number, but not for total OC 
number. *Indicates significant interaction was found between OB genotype and BM 
genotype. †Indicates a significant main effect for OB genotype. ‡Indicates a significant main 
effect for BM genotype.
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Figure 4. 
mRNA expression in WT and c-Mpl−/− OBs. OBs were cultured under osteogenic 
conditions as before for 7 days. Real-time PCR was used to determine mRNA expression of 
M-CSF, OPG, RANKL, Eph B2, and Eph B4. GAPDH was used to normalize the amount of 
the investigated transcript. No significant differences were detected suggesting that c-Mpl 
expression does not affect OB expression of these known regulators of osteoclastogenesis.
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Figure 5. 
Working model depicting the direct and indirect effects of TPO/c-Mpl on skeletal 
homeostasis. In the bone marrow cavity, TPO binds to its receptor c-Mpl on MK/MK 
progenitors and activation of c-Mpl signaling results in proliferation and differentiation of 
MKs. MKs enhance OB proliferation by a direct cell-cell contact mechanism. With 
increased numbers of OBs there is also a net increase in RANKL expression which enhances 
OC differentiation/activation. At the same time, TPO binds to its receptor c-Mpl on OC 
progenitors, stimulating a significant increase in mature OC number. However, increased 
numbers of MKs also inhibit OC formation. Together these actions result in coupled 
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remodeling in WT mice and a net gain in bone mass in TPO overexpressing mice. With c-
Mpl deficiency the opposite is observed with respect to TPO-mediated effects (e.g. effects of 
TPO on MKs and OC progenitors and associated downstream effects). However, an 
important difference is noted; C-Mpl−/− OBs proliferate more than do their WT counterpart 
in vitro and in vivo. Additionally, c-Mpl−/− OBs promote osteoclastogenesis by a yet 
undetermined mechanism. Combined c-Mpl deficiency results in a high turnover state with a 
net gain in bone mass.
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